---
title: Fucoidan Improves the Metabolic Profiles of Patients With Non-alcoholic Fatty Liver Disease (NAFLD)
nct_id: NCT02875392
overall_status: COMPLETED
phase: NA
sponsor: Taipei Medical University WanFang Hospital
study_type: INTERVENTIONAL
primary_condition: Non-alcoholic Fatty Liver Disease
countries: Taiwan
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02875392.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02875392"
ct_last_update_post_date: 2021-04-13
last_seen_at: "2026-05-12T06:33:08.385Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Fucoidan Improves the Metabolic Profiles of Patients With Non-alcoholic Fatty Liver Disease (NAFLD)

**NCT ID:** [NCT02875392](https://clinicaltrials.gov/study/NCT02875392)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 57
- **Lead Sponsor:** Taipei Medical University WanFang Hospital
- **Conditions:** Non-alcoholic Fatty Liver Disease
- **Start Date:** 2016-11
- **Completion Date:** 2018-03
- **CT.gov Last Update:** 2021-04-13

## Brief Summary

Studies reveal special function of fucoidan so far include anti-virus, anti-tumor, immunomodulatory, anti-inflammatory, blood fat, anti-oxidation and liver and kidney dysfunction and improve fibrosis. The subject of this study focus on assessing the impact on the metabolism of fatty liver and liver fibrosis after taking oral FucoHiQ capsules.

## Detailed Description

Fucoidan is a water-soluble dietary fiber which is extracted from brown seaweed. Slimy surface of brown seaweed has unique ingredients and different kind of brown seaweed has slightly different effectiveness. The strongest fucoidan among all seaweed for inhibiting cancer cells is in Okinawa Japanese waters. For chemically speaking, the major components for fucoidan consisted of mainly fucose which is a kind of polysaccharide with strong biological activity. However, patients need to take actual fucoidan in order to reach the best effectiveness for inhibiting cancer cell.

Studies reveal special function of fucoidan so far include anti-virus, anti-tumor, immunomodulatory, anti-inflammatory, blood fat, anti-oxidation and liver and kidney dysfunction and improve fibrosis. The subject of this study focus on assessing the impact on the metabolism of fatty liver and liver fibrosis after taking oral FucoHiQ capsules.

## Eligibility

- **Minimum age:** 20 Years
- **Maximum age:** 75 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* Patients who are aged between 20-75 with non alcoholic fatty liver disease (NAFLD).

Exclusion Criteria:

1. Patients were allergic to seafood.
2. Patients who take Vitamin E or Pioglitazone.
```

## Arms

- **Fucoidan use** (EXPERIMENTAL) — FucoHiQ(275mg Oligo Fucoidan + 275mg HS Fucoxanthin) 550mg/capsule 6 per day(before breakfast and supper)
- **placebo pills** (PLACEBO_COMPARATOR) — placebo capsule 6 per day (before breakfast and supper)

## Interventions

- **275mg Oligo Fucoidan + 275mg HS Fucoxanthin** (OTHER) — Fucoidan is a water-soluble dietary fiber which is extracted from brown seaweed. Slimy surface of brown seaweed has unique ingredients and different kind of brown seaweed has slightly different effectiveness.The subject of this study focus on assessing the impact on the metabolism of fatty liver and liver fibrosis after taking oral FucoHiQ capsules.
- **placebo pills** (OTHER) — taking placebo pills as if patients are under treatment.

## Primary Outcomes

- **Change in ALT Index** _(time frame: 6 months)_ — Measure the first month and the sixth-month change in the index which is ALT related to Liver inflammation.
- **Change in AST Index** _(time frame: 6 months)_ — Measure the first month and the sixth-month change in the index which is AST relate to Liver inflammation
- **Change in HbA1c** _(time frame: 6 months)_ — Measure the first month and the sixth-month change in the index which is HbA1c relate to Liver inflammation

## Locations (1)

- WanFangH, Taipei, Taiwan

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.wanfangh|taipei||taiwan` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02875392.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02875392*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*